

Resource Summary Report

Generated by [NIF](#) on Aug 12, 2026

Anti-Human CD62L (DREG-56)-153Eu

RRID:AB_2810245

Type: Antibody

Proper Citation

(Standard BioTools Cat# 3153004, RRID:AB_2810245)

Antibody Information

URL: http://antibodyregistry.org/AB_2810245

Proper Citation: (Standard BioTools Cat# 3153004, RRID:AB_2810245)

Target Antigen: CD62L/L-selectin

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Mass Cytometry

Antibody Name: Anti-Human CD62L (DREG-56)-153Eu

Description: This monoclonal targets CD62L/L-selectin

Target Organism: bovine, chimpanzee, human

Clone ID: DREG56

Antibody ID: AB_2810245

Vendor: Standard BioTools

Catalog Number: 3153004

Record Creation Time: 20260130T082116+0000

Record Last Update: 20260225T232036+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human CD62L (DREG-56)-153Eu.

No alerts have been found for Anti-Human CD62L (DREG-56)-153Eu.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Ma T, et al. (2026) Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV rebound. *Immunity*, 59(5), 1454.

Wang M, et al. (2025) Comprehensive analysis of B cell repopulation in ocrelizumab-treated patients with multiple sclerosis by mass cytometry and proteomics. *iScience*, 28(5), 112383.

Yoshikawa T, et al. (2024) Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. *Cell reports. Medicine*, 5(5), 101526.

Krämer B, et al. (2021) Early IFN- γ signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. *Immunity*, 54(11), 2650.

Xie G, et al. (2021) Characterization of HIV-induced remodeling reveals differences in infection susceptibility of memory CD4⁺ T cell subsets in vivo. *Cell reports*, 35(4), 109038.

Liu S, et al. (2021) Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. *Cell reports. Medicine*, 2(10), 100411.

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell*, 182(6), 1419.

Colomb F, et al. (2020) Sialyl-LewisX Glycoantigen Is Enriched on Cells with Persistent HIV Transcription during Therapy. *Cell reports*, 32(5), 107991.